Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.67
Quick Ratio6.06
Price-To-Earnings
Trailing P/E Ratio146.93
Forward P/E Ratio108.75
P/E Growth4.78
Sales & Book Value
Annual Sales$249.44 million
Price / Sales16.37
Cash Flow$1.9843 per share
Price / Cash97.00
Book Value$10.88 per share
Price / Book17.69
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$21 million
Net Margins9.36%
Return on Equity14.81%
Return on Assets12.19%
Miscellaneous
Employees770
Outstanding Shares21,220,000
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) posted its quarterly earnings results on Monday, April, 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.29 by $0.19. The medical technology company earned $79.05 million during the quarter, compared to the consensus estimate of $63.86 million. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The company's revenue for the quarter was up 50.6% on a year-over-year basis. During the same period last year, the firm earned $0.27 EPS. View Inogen's Earnings History.
What price target have analysts set for INGN?
5 analysts have issued 1 year price targets for Inogen's stock. Their predictions range from $170.00 to $215.00. On average, they anticipate Inogen's share price to reach $188.75 in the next twelve months. View Analyst Ratings for Inogen.
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. Needham & Company LLC analysts commented, "We hosted for management meetings in Boston and Toronto last week. Recent sales and marketing investments (CRM, training, and new hires) are paying off with higher growth. We think INGN’s DTC channel is a competitive advantage and one that is difficult for competitors to copy. INGN is increasingly spending its R&D dollars on research as opposed to development; we expect it to launch the G5 next year. The US POC market remains significantly underpenetrated and international markets, particularly emerging markets, have minimal penetration. Despite facing some much larger competitors, we believe INGN has the best POCs and that it can maintain its lead. We expect INGN to sustain very strong revenue growth for the next few years and to continue to deliver upside to consensus estimates and we reiterate our Strong Buy rating." (6/13/2018)
- 2. According to Zacks Investment Research, "Inogen ended the fourth quarter of 2017 on a positive note, with earnings and revenues beating the Zacks Consensus Estimate. Promising business-to-business and direct-to-consumer sales growth is encouraging. The company expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a solid growth rate. Inogen will continue to focus on the European markets. Raised revenue guidance for 2018 also instills confidence. On the flip side, declining rental revenues is a concern. Moreover, the international business-to-business sales declined lately. Adding to the woes, the company saw diminishing gross margin and a rise in operating expenses, driven by gradually increasing research and development spending. Stiff competition in the niche space is likely to mar prospects." (3/5/2018)
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), MSA Safety (MSA), Halyard Health (HYH), Wright Medical Group (WMGI), Invacare (IVC), Consort Medical (CSRMY), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX), ConforMIS (CFMS), Rewalk Robotics (RWLK) and COLLPLANT HOLDI/S (CLGN).
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 53)
- Mr. Brenton Taylor, Exec. VP of Engineering (Age 37)
- Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 37)
- Mr. Matthew S. Scribner, Exec. VP of Operations (Age 51)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 39)
Has Inogen been receiving favorable news coverage?
Media headlines about INGN stock have trended positive recently, Accern reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Inogen earned a coverage optimism score of 0.43 on Accern's scale. They also gave press coverage about the medical technology company an impact score of 48.26 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Inogen's major shareholders?
Inogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.40%), Blair William & Co. IL (2.68%), Dimensional Fund Advisors LP (2.32%), New York State Common Retirement Fund (1.72%), Rockefeller Capital Management L.P. (1.40%) and Wells Fargo & Company MN (1.40%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Millennium Management LLC, Royal Bank of Canada, WINTON GROUP Ltd, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Cortina Asset Management LLC and New York State Common Retirement Fund. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Chicago Capital LLC, BlackRock Inc., Rock Springs Capital Management LP, Prudential Financial Inc., State of Wisconsin Investment Board, Wells Fargo & Company MN and OppenheimerFunds Inc.. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $192.48.
How big of a company is Inogen?
Inogen has a market capitalization of $4.03 billion and generates $249.44 million in revenue each year. The medical technology company earns $21 million in net income (profit) each year or $1.31 on an earnings per share basis. Inogen employs 770 workers across the globe.
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
